New vaccine aims to shield older adults from pneumonia
NCT ID NCT07105722
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new vaccine called Pn-MAPS30plus to see if it is safe and helps the body fight pneumonia-causing bacteria. It involved 127 healthy adults aged 50 to 64. The vaccine is designed to protect against more types of the bacteria than current vaccines.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA - BACTERIAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Norwood, South Australia, 5067, Australia
-
GSK Investigational Site
Bayswater, Victoria, 3153, Australia
-
GSK Investigational Site
Camberwell, Victoria, 3124, Australia
-
GSK Investigational Site
East Melbourne, Victoria, 3002, Australia